Genta Receives Orphan-Drug Designation for Leukemia Candidate

March 22, 2005

The FDA has granted orphan-drug designation to Genta for its drug candidate LR3001, a compound intended to treat chronic myelocytic leukemia.

The drug has already been tested in two Phase I clinical trials in patients with myeloid leukemia, and Genta said it plans to pursue further clinical development of the compound in patients with both hematologic cancers and solid tumors.